当前位置：
X-MOL 学术
›
Cell Death Differ.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells.
Cell Death and Differentiation ( IF 12.4 ) Pub Date : 2020-06-18 , DOI: 10.1038/s41418-020-0576-2 Rachel Thijssen 1, 2 , Silvia Alvarez-Diaz 1, 2 , Clea Grace 1, 3 , Ming-Yuan Gao 1, 2 , David H Segal 1, 2 , Zhen Xu 1, 2 , Andreas Strasser 1, 2 , David C S Huang 1, 2
中文翻译：
RIPK3 的缺失不影响 MYC 驱动的淋巴瘤发生或化疗药物诱导的恶性淋巴瘤细胞杀伤。
更新日期：2020-06-18
Cell Death and Differentiation ( IF 12.4 ) Pub Date : 2020-06-18 , DOI: 10.1038/s41418-020-0576-2 Rachel Thijssen 1, 2 , Silvia Alvarez-Diaz 1, 2 , Clea Grace 1, 3 , Ming-Yuan Gao 1, 2 , David H Segal 1, 2 , Zhen Xu 1, 2 , Andreas Strasser 1, 2 , David C S Huang 1, 2
Affiliation
中文翻译：
RIPK3 的缺失不影响 MYC 驱动的淋巴瘤发生或化疗药物诱导的恶性淋巴瘤细胞杀伤。
京公网安备 11010802027423号